Matthew Perez


  • New York Super Lawyers Rising Star (2019-present)
  • The Legal 500: “Rising Star” (2020-2022)
  • Member of the New York State Bar Association Antitrust Section’s Executive Committee


Matt Perez is a Partner in Scott+Scott’s New York office.  Mr. Perez focuses on antitrust and competition litigation, class action and commercial litigation.

Matt represents consumers, businesses, public pension funds, and insurers in complex antitrust class actions.  His practice spans a wide range of industries, but with particular focus on

pharmaceuticals and financial services.  He has litigated (including through trial) several pay-for-delay antitrust actions on behalf of consumers, health plans, and insurers alleging delayed generic entry for Exforge, Opana ER, Xyrem, and Zetia, among others.  He has or is currently representing investors in financial services and commodity markets, including pension funds and traders in foreign exchange, international sovereign bonds, interest rate and credit derivatives, and commodity futures markets.  Most recently, he has litigated alleged no-poach agreements affecting engineers and other skilled workers employed by aerospace companies.  Matt is skilled in all phases of litigation, including trial and appeals, having recently tried a pharmaceutical reverse payment matter to verdict and successfully argued an antitrust matter before the Second Circuit.

Prior to joining Scott+Scott, Matt worked for a nationally recognized class action law firm and the New York State Office of the Attorney General Antitrust Bureau.  At the New York Attorney General’s Office, he received the Louis J. Lefkowitz Memorial Award for his work investigating bid rigging and other illegal conduct in the municipal bond derivatives market, resulting in more than $260 million in restitution to municipalities and nonprofit entities.

Matt has been recognized by industry publications, including the Legal 500 (Rising Star) and New York Super Lawyers (Rising Star).  He is also a member of the Executive Committee of the New York State Bar Association’s Antitrust Section.


  • In re European Government Bonds Antitrust Litigation, No. 1:19-cv-02601 (S.D.N.Y.) ($40 million in partial settlements)
  • In re Foreign Exchange Benchmark Rates Antitrust Litigation, No. 1:13-cv-07789 (S.D.N.Y.) ($2.3 billion in settlements)
  • Alaska Electrical Pension Fund, et al. v. Bank of America, et al., No. 14-cv-7126 (S.D.N.Y) (over $500 million in settlements)
  • In re Platinum and Palladium Antitrust Litigation, No. 1:14-cv-9391 (S.D.N.Y.)
  • In re Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2:16-md-02724 (E.D. Pa.)
  • Borozny et al. v. RTX Corp., Pratt & Whitney Division, et al., No. 3:21-cv-1657 (D. Conn.) ($16.6 million in partial settlements)
  • In re Novartis & Par Antitrust Litigation, No. 1:18-cv-4361 (S.D.N.Y.) ($30 million settlement)
  • In re Opana ER Antitrust Litigation, No. 1:14-cv-10150 (N.D. Ill.) ($15 million settlement)
  • In re Aftermarket Automotive Lighting Products Antitrust Litigation, No. 09-MDL-2007 (over $50 million in settlements)